Page 6 - Spring 2021 Newsletter

Guidelines Report
• Non-muscle-invasive bladder cancer (will be presented at
Bobby Shayegan CUA Night School 2021)
Chair, Guidelines Committee • Ureteral calculi (will be presented at CUA Night School 2021)
Hamilton, ON
• Erectile dysfunction
• Bone health in prostate cancer
• Post-prostatectomy incontinence
Guidelines, best practice reports, and consensus
statements released since the start of 2021: • Asymptomatic microscopic hematuria
• Pediatric bladder dysfunction • Nocturia
• CRPC 2021 update & overview of changes since 2019 • Azoospermic males
• Testosterone deficiency in men (will be presented at • Small renal masses
CUA Night School 2021) • Testicular germ cell cancer
• PSMA PET-CT in prostate cancer (BPR) • Interstitial cystitis/bladder pain syndrome
• KCRNC consensus statement on advanced renal cell • Penile cancer
carcinoma
• Small testicular masses
Visit cuaj.org or cua.org to view both English and French • Screening for Lynch II patients
versions of all guidelines.
We recently welcomed new Guidelines Committee members
Some of the topics for which guidelines/BPRs are currently Naeem Bhojani (Montreal) and Michael Ordon (Toronto).
being developed or are in the process of being updated:
• Androgen deprivation therapy: adverse events and If you would like to be part of the Committee or have a
management strategies (will be presented at CUA suggestion for a relevant guideline, please contact the CUA
Night School 2021) Guidelines Manager at adriana.modica@cua.org.

New Indication
in Canada

Xtandi is now indicated for the
NEW treatment of patients with metastatic
castration-sensitive prostate cancer
(mCSPC).

Other Indications: Please consult the product monograph at https://www.astellas.com/
Xtandi® (enzalutamide capsules) is indicated for the treatment of ca/system/fi les/2020-06/Xtandi_PM_EN_June2020.pdf for
patients with non-metastatic castration-resistant prostate cancer contraindications, warnings, precautions, adverse reactions,
(nmCRPC). Xtandi has not been studied in patients with nmCRPC interactions, dosing and conditions of clinical use. The product
1
at low risk of developing metastatic disease. The benefi t and risk monograph is also available by calling 1-888-338-1824.
profi le in these patients is unknown. 1 Reference: 1. Xtandi Product Monograph. Astellas Pharma Canada, Inc. June 1, 2020.
Xtandi is also indicated in the setting of medical or surgical castration
for the treatment of metastatic castration-resistant prostate cancer
(mCRPC) in patients who: 1
• are chemotherapy-naïve with asymptomatic or mildly symptomatic
disease after failure of androgen deprivation therapy. 1
• have received docetaxel therapy. 1
Xtandi® is a registered trademark of Astellas Pharma Inc. © 2021 Astellas Pharma Canada, Inc. All rights reserved.
076-5522-PM-EN

6 21222d_Astellas-CUANewsletterAdEN_REL_C00_00_.indd 1 2021-03-31 2:20 PM